<!DOCTYPE html>
<html>
  <script>
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
  })(window,document,'script','https://www.google-analytics.com/analytics.js','ga');

  ga('create', 'UA-79742963-1', 'auto');
  ga('send', 'pageview');

</script>

  <!-- Begin Jekyll SEO tag v2.5.0 -->
<title>What’s new for ‘ACE inhibitors and cancer’ in PubMed | Ciência médica</title>
<meta name="generator" content="Jekyll v3.7.4" />
<meta property="og:title" content="What’s new for ‘ACE inhibitors and cancer’ in PubMed" />
<meta name="author" content="Francisco H C Felix" />
<meta property="og:locale" content="en" />
<meta name="description" content="This message contains My NCBI what’s new results from the National Center for BiotechnologySender’s message: Sent on Saturday, 2011 Sep 17Search angiotensin cancer &lt;div&gt;&lt;div&gt;&lt;table bgcolor=&quot;#CCCCCC&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;PubMed Results&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;Item 1 of 1&lt;/div&gt;&lt;div&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;5&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap=&quot;nowrap&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;1.&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Angiotensin converting enzyme inhibitors and hepatocellular carcinoma incidence in the General Practice Research Database.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Walker AJ, West J, Grainge MJ, Card TR.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Cancer Causes Control. 2011 Sep 11. [Epub ahead of print]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;&lt;div class=&quot;abstr&quot;&gt;&lt;h3&gt; Abstract&lt;/h3&gt;&lt;h4&gt; OBJECTIVE: &lt;/h4&gt;Laboratory findings demonstrate anticancer effects of angiotensin converting enzyme (ACE) inhibitors, including anti-angiogenic activity and inhibition of liver cancer growth in rodent models. Small studies in humans indicate potential for therapeutic anticancer effects and warrant further larger studies.&lt;h4&gt; METHODS: &lt;/h4&gt;A case-control study using the General Practice Research Database examined whether prior ACE inhibitor usage was associated with a reduction in incidence of hepatocellular carcinoma (HCC).&lt;h4&gt; RESULTS: &lt;/h4&gt;Two hundred twenty-four HCC cases were identified, each matched to up to 10 controls by age, sex, and general practice. The data show that HCC is associated with a small, nonsignificant increase in prior use of ACE inhibitors (OR = 1.16, CI = 0.67-2.00). ACE inhibitor use was 7.1% (of 224) in cases and 5.9% (of 2,313) in controls. No significant effects were found when investigating the effect of dose and exposure duration.&lt;h4&gt; CONCLUSIONS: &lt;/h4&gt;We found no clear protective effect of ever or long term use of ACE inhibitors against the development of HCC. Our study suggests that it is unlikely that this class of drugs will be a clinically useful cancer chemoprevention therapy.&lt;/div&gt;PMID: 21909951 [PubMed - as supplied by publisher]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;" />
<meta property="og:description" content="This message contains My NCBI what’s new results from the National Center for BiotechnologySender’s message: Sent on Saturday, 2011 Sep 17Search angiotensin cancer &lt;div&gt;&lt;div&gt;&lt;table bgcolor=&quot;#CCCCCC&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;PubMed Results&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;Item 1 of 1&lt;/div&gt;&lt;div&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;5&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap=&quot;nowrap&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;1.&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Angiotensin converting enzyme inhibitors and hepatocellular carcinoma incidence in the General Practice Research Database.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Walker AJ, West J, Grainge MJ, Card TR.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Cancer Causes Control. 2011 Sep 11. [Epub ahead of print]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;&lt;div class=&quot;abstr&quot;&gt;&lt;h3&gt; Abstract&lt;/h3&gt;&lt;h4&gt; OBJECTIVE: &lt;/h4&gt;Laboratory findings demonstrate anticancer effects of angiotensin converting enzyme (ACE) inhibitors, including anti-angiogenic activity and inhibition of liver cancer growth in rodent models. Small studies in humans indicate potential for therapeutic anticancer effects and warrant further larger studies.&lt;h4&gt; METHODS: &lt;/h4&gt;A case-control study using the General Practice Research Database examined whether prior ACE inhibitor usage was associated with a reduction in incidence of hepatocellular carcinoma (HCC).&lt;h4&gt; RESULTS: &lt;/h4&gt;Two hundred twenty-four HCC cases were identified, each matched to up to 10 controls by age, sex, and general practice. The data show that HCC is associated with a small, nonsignificant increase in prior use of ACE inhibitors (OR = 1.16, CI = 0.67-2.00). ACE inhibitor use was 7.1% (of 224) in cases and 5.9% (of 2,313) in controls. No significant effects were found when investigating the effect of dose and exposure duration.&lt;h4&gt; CONCLUSIONS: &lt;/h4&gt;We found no clear protective effect of ever or long term use of ACE inhibitors against the development of HCC. Our study suggests that it is unlikely that this class of drugs will be a clinically useful cancer chemoprevention therapy.&lt;/div&gt;PMID: 21909951 [PubMed - as supplied by publisher]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;" />
<link rel="canonical" href="http://fhcflx.github.io/ciencia-medica/2011/09/17/whats-new-for-ace-inhibitors-and-cancer.html" />
<meta property="og:url" content="http://fhcflx.github.io/ciencia-medica/2011/09/17/whats-new-for-ace-inhibitors-and-cancer.html" />
<meta property="og:site_name" content="Ciência médica" />
<meta property="og:type" content="article" />
<meta property="article:published_time" content="2011-09-17T12:54:00-03:00" />
<script type="application/ld+json">
{"description":"This message contains My NCBI what’s new results from the National Center for BiotechnologySender’s message: Sent on Saturday, 2011 Sep 17Search angiotensin cancer &lt;div&gt;&lt;div&gt;&lt;table bgcolor=&quot;#CCCCCC&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;PubMed Results&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;Item 1 of 1&lt;/div&gt;&lt;div&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;5&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap=&quot;nowrap&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;1.&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Angiotensin converting enzyme inhibitors and hepatocellular carcinoma incidence in the General Practice Research Database.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Walker AJ, West J, Grainge MJ, Card TR.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Cancer Causes Control. 2011 Sep 11. [Epub ahead of print]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;&lt;div class=&quot;abstr&quot;&gt;&lt;h3&gt; Abstract&lt;/h3&gt;&lt;h4&gt; OBJECTIVE: &lt;/h4&gt;Laboratory findings demonstrate anticancer effects of angiotensin converting enzyme (ACE) inhibitors, including anti-angiogenic activity and inhibition of liver cancer growth in rodent models. Small studies in humans indicate potential for therapeutic anticancer effects and warrant further larger studies.&lt;h4&gt; METHODS: &lt;/h4&gt;A case-control study using the General Practice Research Database examined whether prior ACE inhibitor usage was associated with a reduction in incidence of hepatocellular carcinoma (HCC).&lt;h4&gt; RESULTS: &lt;/h4&gt;Two hundred twenty-four HCC cases were identified, each matched to up to 10 controls by age, sex, and general practice. The data show that HCC is associated with a small, nonsignificant increase in prior use of ACE inhibitors (OR = 1.16, CI = 0.67-2.00). ACE inhibitor use was 7.1% (of 224) in cases and 5.9% (of 2,313) in controls. No significant effects were found when investigating the effect of dose and exposure duration.&lt;h4&gt; CONCLUSIONS: &lt;/h4&gt;We found no clear protective effect of ever or long term use of ACE inhibitors against the development of HCC. Our study suggests that it is unlikely that this class of drugs will be a clinically useful cancer chemoprevention therapy.&lt;/div&gt;PMID: 21909951 [PubMed - as supplied by publisher]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;","author":{"@type":"Person","name":"Francisco H C Felix"},"@type":"BlogPosting","url":"http://fhcflx.github.io/ciencia-medica/2011/09/17/whats-new-for-ace-inhibitors-and-cancer.html","headline":"What’s new for ‘ACE inhibitors and cancer’ in PubMed","dateModified":"2011-09-17T12:54:00-03:00","datePublished":"2011-09-17T12:54:00-03:00","mainEntityOfPage":{"@type":"WebPage","@id":"http://fhcflx.github.io/ciencia-medica/2011/09/17/whats-new-for-ace-inhibitors-and-cancer.html"},"@context":"http://schema.org"}</script>
<!-- End Jekyll SEO tag -->

  <head>
  <meta charset="utf-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1">

  <!-- Begin Jekyll SEO tag v2.5.0 -->
<title>What’s new for ‘ACE inhibitors and cancer’ in PubMed | Ciência médica</title>
<meta name="generator" content="Jekyll v3.7.4" />
<meta property="og:title" content="What’s new for ‘ACE inhibitors and cancer’ in PubMed" />
<meta name="author" content="Francisco H C Felix" />
<meta property="og:locale" content="en" />
<meta name="description" content="This message contains My NCBI what’s new results from the National Center for BiotechnologySender’s message: Sent on Saturday, 2011 Sep 17Search angiotensin cancer &lt;div&gt;&lt;div&gt;&lt;table bgcolor=&quot;#CCCCCC&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;PubMed Results&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;Item 1 of 1&lt;/div&gt;&lt;div&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;5&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap=&quot;nowrap&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;1.&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Angiotensin converting enzyme inhibitors and hepatocellular carcinoma incidence in the General Practice Research Database.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Walker AJ, West J, Grainge MJ, Card TR.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Cancer Causes Control. 2011 Sep 11. [Epub ahead of print]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;&lt;div class=&quot;abstr&quot;&gt;&lt;h3&gt; Abstract&lt;/h3&gt;&lt;h4&gt; OBJECTIVE: &lt;/h4&gt;Laboratory findings demonstrate anticancer effects of angiotensin converting enzyme (ACE) inhibitors, including anti-angiogenic activity and inhibition of liver cancer growth in rodent models. Small studies in humans indicate potential for therapeutic anticancer effects and warrant further larger studies.&lt;h4&gt; METHODS: &lt;/h4&gt;A case-control study using the General Practice Research Database examined whether prior ACE inhibitor usage was associated with a reduction in incidence of hepatocellular carcinoma (HCC).&lt;h4&gt; RESULTS: &lt;/h4&gt;Two hundred twenty-four HCC cases were identified, each matched to up to 10 controls by age, sex, and general practice. The data show that HCC is associated with a small, nonsignificant increase in prior use of ACE inhibitors (OR = 1.16, CI = 0.67-2.00). ACE inhibitor use was 7.1% (of 224) in cases and 5.9% (of 2,313) in controls. No significant effects were found when investigating the effect of dose and exposure duration.&lt;h4&gt; CONCLUSIONS: &lt;/h4&gt;We found no clear protective effect of ever or long term use of ACE inhibitors against the development of HCC. Our study suggests that it is unlikely that this class of drugs will be a clinically useful cancer chemoprevention therapy.&lt;/div&gt;PMID: 21909951 [PubMed - as supplied by publisher]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;" />
<meta property="og:description" content="This message contains My NCBI what’s new results from the National Center for BiotechnologySender’s message: Sent on Saturday, 2011 Sep 17Search angiotensin cancer &lt;div&gt;&lt;div&gt;&lt;table bgcolor=&quot;#CCCCCC&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;PubMed Results&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;Item 1 of 1&lt;/div&gt;&lt;div&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;5&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap=&quot;nowrap&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;1.&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Angiotensin converting enzyme inhibitors and hepatocellular carcinoma incidence in the General Practice Research Database.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Walker AJ, West J, Grainge MJ, Card TR.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Cancer Causes Control. 2011 Sep 11. [Epub ahead of print]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;&lt;div class=&quot;abstr&quot;&gt;&lt;h3&gt; Abstract&lt;/h3&gt;&lt;h4&gt; OBJECTIVE: &lt;/h4&gt;Laboratory findings demonstrate anticancer effects of angiotensin converting enzyme (ACE) inhibitors, including anti-angiogenic activity and inhibition of liver cancer growth in rodent models. Small studies in humans indicate potential for therapeutic anticancer effects and warrant further larger studies.&lt;h4&gt; METHODS: &lt;/h4&gt;A case-control study using the General Practice Research Database examined whether prior ACE inhibitor usage was associated with a reduction in incidence of hepatocellular carcinoma (HCC).&lt;h4&gt; RESULTS: &lt;/h4&gt;Two hundred twenty-four HCC cases were identified, each matched to up to 10 controls by age, sex, and general practice. The data show that HCC is associated with a small, nonsignificant increase in prior use of ACE inhibitors (OR = 1.16, CI = 0.67-2.00). ACE inhibitor use was 7.1% (of 224) in cases and 5.9% (of 2,313) in controls. No significant effects were found when investigating the effect of dose and exposure duration.&lt;h4&gt; CONCLUSIONS: &lt;/h4&gt;We found no clear protective effect of ever or long term use of ACE inhibitors against the development of HCC. Our study suggests that it is unlikely that this class of drugs will be a clinically useful cancer chemoprevention therapy.&lt;/div&gt;PMID: 21909951 [PubMed - as supplied by publisher]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;" />
<link rel="canonical" href="http://fhcflx.github.io/ciencia-medica/2011/09/17/whats-new-for-ace-inhibitors-and-cancer.html" />
<meta property="og:url" content="http://fhcflx.github.io/ciencia-medica/2011/09/17/whats-new-for-ace-inhibitors-and-cancer.html" />
<meta property="og:site_name" content="Ciência médica" />
<meta property="og:type" content="article" />
<meta property="article:published_time" content="2011-09-17T12:54:00-03:00" />
<script type="application/ld+json">
{"description":"This message contains My NCBI what’s new results from the National Center for BiotechnologySender’s message: Sent on Saturday, 2011 Sep 17Search angiotensin cancer &lt;div&gt;&lt;div&gt;&lt;table bgcolor=&quot;#CCCCCC&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;PubMed Results&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;Item 1 of 1&lt;/div&gt;&lt;div&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;5&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap=&quot;nowrap&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;1.&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Angiotensin converting enzyme inhibitors and hepatocellular carcinoma incidence in the General Practice Research Database.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Walker AJ, West J, Grainge MJ, Card TR.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Cancer Causes Control. 2011 Sep 11. [Epub ahead of print]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;&lt;div class=&quot;abstr&quot;&gt;&lt;h3&gt; Abstract&lt;/h3&gt;&lt;h4&gt; OBJECTIVE: &lt;/h4&gt;Laboratory findings demonstrate anticancer effects of angiotensin converting enzyme (ACE) inhibitors, including anti-angiogenic activity and inhibition of liver cancer growth in rodent models. Small studies in humans indicate potential for therapeutic anticancer effects and warrant further larger studies.&lt;h4&gt; METHODS: &lt;/h4&gt;A case-control study using the General Practice Research Database examined whether prior ACE inhibitor usage was associated with a reduction in incidence of hepatocellular carcinoma (HCC).&lt;h4&gt; RESULTS: &lt;/h4&gt;Two hundred twenty-four HCC cases were identified, each matched to up to 10 controls by age, sex, and general practice. The data show that HCC is associated with a small, nonsignificant increase in prior use of ACE inhibitors (OR = 1.16, CI = 0.67-2.00). ACE inhibitor use was 7.1% (of 224) in cases and 5.9% (of 2,313) in controls. No significant effects were found when investigating the effect of dose and exposure duration.&lt;h4&gt; CONCLUSIONS: &lt;/h4&gt;We found no clear protective effect of ever or long term use of ACE inhibitors against the development of HCC. Our study suggests that it is unlikely that this class of drugs will be a clinically useful cancer chemoprevention therapy.&lt;/div&gt;PMID: 21909951 [PubMed - as supplied by publisher]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;","author":{"@type":"Person","name":"Francisco H C Felix"},"@type":"BlogPosting","url":"http://fhcflx.github.io/ciencia-medica/2011/09/17/whats-new-for-ace-inhibitors-and-cancer.html","headline":"What’s new for ‘ACE inhibitors and cancer’ in PubMed","dateModified":"2011-09-17T12:54:00-03:00","datePublished":"2011-09-17T12:54:00-03:00","mainEntityOfPage":{"@type":"WebPage","@id":"http://fhcflx.github.io/ciencia-medica/2011/09/17/whats-new-for-ace-inhibitors-and-cancer.html"},"@context":"http://schema.org"}</script>
<!-- End Jekyll SEO tag -->


  <!--
  -->
 <link rel="alternate" type="application/rss+xml" title="" href="/ciencia-medica">

  <title>What's new for 'ACE inhibitors and cancer' in PubMed</title>
  <meta name="description" content="This message contains My NCBI what's new results from the National Center for BiotechnologySender's message:  Sent on Saturday, 2011 Sep 17Search angiotensin...">

  <!-- Google Fonts loaded here depending on setting in _data/options.yml true loads font, blank does not-->
  
    <link href='//fonts.googleapis.com/css?family=Lato:400,400italic' rel='stylesheet' type='text/css'>
  

  <!-- Load up MathJax script if needed ... specify in /_data/options.yml file-->
  
    <script type="text/javascript" src="//cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
  

  <link rel="stylesheet" type="text/css" href="/ciencia-medica/css/tufte.css">
  <!-- <link rel="stylesheet" type="text/css" href="/ciencia-medica/css/print.css" media="print"> -->

  <link rel="canonical" href="http://fhcflx.github.io/ciencia-medica/2011/09/17/whats-new-for-ace-inhibitors-and-cancer.html">
  <link rel="icon"
        type="image/png"
        href="/assets/img/badge.png">

  <link rel="alternate" type="application/rss+xml" title="Ciência médica" href="http://fhcflx.github.io/ciencia-medica/feed.xml" />

  <link rel="apple-touch-icon" sizes="180x180" href="/ciencia-medica/apple-touch-icon.png">
  <link rel="icon" type="image/png" sizes="32x32" href="/ciencia-medica/favicon-32x32.png">
  <link rel="icon" type="image/png" sizes="16x16" href="/ciencia-medica/favicon-16x16.png">
  <link rel="manifest" href="/ciencia-medica/site.webmanifest">
  <link rel="mask-icon" href="/ciencia-medica/safari-pinned-tab.svg" color="#5bbad5">
  <link rel="shortcut icon" href="/ciencia-medica/favicon.ico">
  <meta name="msapplication-TileColor" content="#da532c">
  <meta name="msapplication-config" content="/ciencia-medica/browserconfig.xml">
  <meta name="theme-color" content="#ffffff">

</head>

  <body>
    <!--- Hader and nav template site-wide -->
<header>
    <a class="site-title" href="/ciencia-medica/"></a>
    <nav class="group">
	<a href="/ciencia-medica/"><img class="badge" src="/ciencia-medica/assets/img/mybadge.png" alt="CH"></a>
        
	
		
		    
		      <a href="/ciencia-medica/index.html">Medical Science</a>
		    
	    
  	
		
		    
		      <a href="/ciencia-medica/all-posts/index.html">All</a>
		    
	    
  	
		
		    
		      <a href="/ciencia-medica/vascular/index.html">Vascular anomalies</a>
		    
	    
  	
		
		    
		      <a href="/ciencia-medica/cancer2/index.html">Cancer</a>
		    
	    
  	
		
		    
		      <a href="/ciencia-medica/markers/index.html">Tags</a>
		    
	    
  	
		
		    
		      <a href="/ciencia-medica/about/index.html">About</a>
		    
	    
  	
        <!--<div class="trigger">
            
            
               
               <a class="page-link" href="/ciencia-medica/index.html">Medical Science</a>
               
            
               
               <a class="page-link" href="/ciencia-medica/all-posts/index.html">All</a>
               
            
               
               <a class="page-link" href="/ciencia-medica/vascular/index.html">Vascular anomalies</a>
               
            
               
               <a class="page-link" href="/ciencia-medica/cancer2/index.html">Cancer</a>
               
            
               
               <a class="page-link" href="/ciencia-medica/markers/index.html">Tags</a>
               
            
               
               <a class="page-link" href="/ciencia-medica/about/index.html">About</a>
               
            
            </div>-->
  </nav>
<div class="wrapper" style="text-align: right; line-height: 2em">
  
  

  
  
</div>
</header>

    <article class="group">
      <h1>What's new for 'ACE inhibitors and cancer' in PubMed</h1>
<p class="subtitle">

17
Setembro
  
2011</p>





<ul class="tags">
  
    <li><a href="/ciencia-medica/marcadores#Cancer" class="tag">Cancer</a></li>
  
</ul>

This message contains My NCBI what's new results from the National Center for Biotechnology<br /><b>Sender's message: </b> <br />Sent on Saturday, 2011 Sep 17<br />Search <b>angiotensin cancer</b> <br /><div><br /><br /><div><table bgcolor="#CCCCCC"><tbody><tr><td align="center">PubMed Results</td></tr></tbody></table>Item 1 of 1</div><br /><div><table cellpadding="0" cellspacing="5"><tbody><tr><td nowrap="nowrap" valign="top" width="10">1.</td><td valign="top"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21909951" ref="ordinalpos=1">Angiotensin converting enzyme inhibitors and hepatocellular carcinoma incidence in the General Practice Research Database.</a></td></tr><tr><td align="left" valign="top" width="10"><br /></td><td align="left" valign="top"><b>Walker AJ,  West J,  Grainge MJ,  Card TR.</b></td></tr><tr><td align="left" valign="top" width="10"><br /></td><td align="left" valign="top"><span class="jrnl" title="Cancer causes &amp; control : CCC">Cancer Causes Control</span>. 2011 Sep 11. [Epub ahead of print]</td></tr><tr><td align="left" valign="top" width="10"><br /></td><td align="left" valign="top"><div class="abstr"><h3> Abstract</h3><h4> OBJECTIVE: </h4>Laboratory  findings demonstrate anticancer effects of angiotensin converting enzyme  (ACE) inhibitors, including anti-angiogenic activity and inhibition of  liver cancer growth in rodent models. Small studies in humans indicate  potential for therapeutic anticancer effects and warrant further larger  studies.<br /><h4> METHODS: </h4>A case-control study using the General  Practice Research Database examined whether prior ACE inhibitor usage  was associated with a reduction in incidence of hepatocellular carcinoma  (HCC).<br /><h4> RESULTS: </h4>Two hundred twenty-four HCC cases were  identified, each matched to up to 10 controls by age, sex, and general  practice. The data show that HCC is associated with a small,  nonsignificant increase in prior use of ACE inhibitors (OR&nbsp;=&nbsp;1.16,  CI&nbsp;=&nbsp;0.67-2.00). ACE inhibitor use was 7.1% (of 224) in cases and 5.9%  (of 2,313) in controls. No significant effects were found when  investigating the effect of dose and exposure duration.<br /><h4> CONCLUSIONS: </h4>We  found no clear protective effect of ever or long term use of ACE  inhibitors against the development of HCC. Our study suggests that it is  unlikely that this class of drugs will be a clinically useful cancer  chemoprevention therapy.</div><br />PMID: 21909951 [PubMed - as supplied by publisher]</td></tr><tr><td align="left" valign="top" width="10"><br /></td><td><br /></td></tr></tbody></table></div></div>


<article style="max-width: 90%;">
  <div id="disqus_thread"></div>
  <script>
    /**
     *  RECOMMENDED CONFIGURATION VARIABLES: EDIT AND UNCOMMENT THE SECTION BELOW TO INSERT DYNAMIC VALUES FROM YOUR PLATFORM OR CMS.
     *  LEARN WHY DEFINING THESE VARIABLES IS IMPORTANT: https://disqus.com/admin/universalcode/#configuration-variables
     */
    /*
    var disqus_config = function () {
        this.page.url = PAGE_URL;  // Replace PAGE_URL with your page's canonical URL variable
        this.page.identifier = PAGE_IDENTIFIER; // Replace PAGE_IDENTIFIER with your page's unique identifier variable
    };
    */
      (function() {  // DON'T EDIT BELOW THIS LINE
          var d = document, s = d.createElement('script');
              s.src = '//pharmak-on.disqus.com/embed.js';

            s.setAttribute('data-timestamp', +new Date());
            (d.head || d.body).appendChild(s);
        })();
  </script>
  <noscript>Please enable JavaScript to view the <a href="https://disqus.com/?ref_noscript" rel="nofollow">comments powered by Disqus.</a></noscript>
</article>


    </article>
    <span class="print-footer">What's new for 'ACE inhibitors and cancer' in PubMed - September 17, 2011 - fhcflx</span>
    <footer>
  <hr class="slender">
  <ul class="footer-links">
    <li><a href="mailto:fhcflx@outlook.com"><span class="icon-mail"></span></a></li>
    
      <li>
        <a href="//www.twitter.com/fhcflx"><span class="icon-twitter"></span></a>
      </li>
    
      <li>
        <a href="//plus.google.com/+FranciscoHCFelix"><span class="icon-googleplus"></span></a>
      </li>
    
      <li>
        <a href="//github.com/fhcflx/ciencia-medica"><span class="icon-github"></span></a>
      </li>
    
      <li>
        <a href="//www.flickr.com/photos/fhcflx"><span class="icon-flickr"></span></a>
      </li>
    
      <li>
        <a href=""><span class="icon-feed"></span></a>
      </li>
    
    <li><a href=https://travis-ci.org/fhcflx/ciencia-medica ><img alt='travis-ci build' src=https://img.shields.io/travis/fhcflx/ciencia-medica.svg?colorA=a00000&colorB=a00000></a></li>
  </ul>
<div class="credits">
<span>&copy; 2019 &nbsp;&nbsp;FHCFLX</span></br> <br>
<span>Este sítio foi criado com o <a href="//github.com/clayh53/tufte-jekyll">tema Tufte para Ciência médica </a> no <a href="//jekyllrb.com">Jekyll</a>.</span>
</div>
</footer>

  </body>
</html>
